Perceptions and Preferences for Defining Biosimilar Products in Prescription Drug Promotion

References

1. 1.↵
   U.S. Food and Drug Administration. Biological Product Definitions. Available at: https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf.
2. 2.↵
   American Cancer Society. List of Biosimilars Used in Cancer Treatment. Available at: https://www.cancer.org/cancer/managing-cancer/treatment-types/biosimilar-drugs/list.html.
3. 3.↵
   1. Padda IS,
   2. Bhatt R,
   3. Rehman O,
   4. Parmar M

   . Biosimilars Use in Medicine for Inflammatory Diseases. 2023. National Center for Biotechnology Information. January. Available at https://www.ncbi.nlm.nih.gov/books/NBK574572/.
4. 4.↵
   U.S. Food and Drug Administration. Biosimilars. Available at https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars.
5. 5.↵
   1. Cohen H,
   2. Beydoun D,
   3. Chien D,
   4. et al

   . Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther 2017;33:2160–72.

   OpenUrlPubMed
6. 6.↵
   1. Price SM,
   2. O'Donoghue AC,
   3. Rizzo L,
   4. Sapru S,
   5. Aikin KJ

   . What influences healthcare providers’ prescribing decisions? Results from a national survey. Res Social Adm Pharm 2021;17:1770–9.

   OpenUrlPubMed
7. 7.↵
   1. Olave M,
   2. Lavery C,
   3. Leonard CE,
   4. et al

   . Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs Ther Perspect 2021;37:338–46.

   OpenUrlPubMed
8. 8.
   1. Kolbe AR,
   2. Kearsley A,
   3. Merchant L,
   4. et al

   . Physician understanding and willingness to prescribe biosimilars: Findings from a US national survey. Biodrugs 2021;35:363–72.

   OpenUrlPubMed
9. 9.↵
   1. Sarnola K,
   2. Merikoski M,
   3. Jyrkka J,
   4. Hameen-Anttila K

   . Physicians' perceptions of the uptake of biosimilars: a systematic review. BMJ Open 2020;10:e034183.

   OpenUrlPubMed
10. 10.↵
    1. Herndon K,
    2. Braithwaite J,
    3. Berry B,
    4. Bourget K

    . Biosimilar perceptions among healthcare professionals and commercial medical benefit policy analysis in the United States. Biodrugs 2021;35:103–12.

    OpenUrlPubMed
11. 11.↵
    1. Jacobs I,
    2. Singh E,
    3. Sewell KL,
    4. Al-Sabbagh A,
    5. Shane LG

    . Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence 2016;10:937–48.

    OpenUrlPubMed
12. 12.
    1. Gibofsky A,
    2. Evans C,
    3. Strand V

    . Provider and patient knowledge gaps on biosimilars: insights from surveys. Am J Manag Care 2022;28:S227–S233.

    OpenUrlPubMed
13. 13.↵
    Statista. Knowledge about biosimilars among consumers in the United States as of 2015. Available at: https://www.statista.com/statistics/503911/consumers-knowledge-about-biosimilars-in-the-us/.
14. 14.↵
    U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Promotional labeling and advertising considerations for prescription biological reference and biosimilar products questions and answers: Guidance for industry. 2020. February. Available at: https://www.fda.gov/media/134862/download.
15. 15.↵
    1. Aikin KJ,
    2. Betts KR,
    3. Southwell BG,
    4. Boudewyns V,
    5. Johnson M,
    6. Breslav ADS

    . Consumer reactions to price comparison and disclosure information in prescription drug print advertising. J Consumer Aff 2019;53:1255–72.

    OpenUrl
16. 16.
    1. Betts KR,
    2. Aikin KJ,
    3. Boudewyns V,
    4. Johnson M,
    5. Stine A,
    6. Southwell BG

    . Physician response to contextualized price-comparison claims in prescription drug advertising. J Commun Healthc 2017;10:195–204.

    OpenUrlPubMed
17. 17.
    1. Boudewyns V,
    2. O'Donoghue AC,
    3. Paquin RS,
    4. Aikin KJ,
    5. Ferriola-Bruckenstein K,
    6. Scott VM

    . Physician interpretation of data of uncertain clinical utility in oncology prescription drug promotion. Oncologist 2021;26:1071–8.

    OpenUrlPubMed
18. 18.
    1. Ju L

    . Thinking about fair balance: how prescription drug advertising disclosure prominence works? IJPHM 2017;11:2–15.

    OpenUrl
19. 19.↵
    1. Wogalter MS,
    2. Shaver EF,
    3. Kalsher MJ

    . Effect of presentation modality in direct-to-consumer (DTC) prescription drug television advertisement. Appl Ergon 2014;45:1330–6.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Kelly BJ,
    2. Rupert DJ,
    3. Aikin KJ,
    4. et al

    . Development and validation of prescription drug risk, efficacy, and benefit perception measures in the context of direct-to-consumer prescription drug advertising. Res Social Adm Pharm 2021;17:942–55.

    OpenUrlPubMed
21. 21.↵
    1. Cohen J

    . Statistical power analysis for the behavioral sciences (2nd ed.). Erlbaum. 1988.
22. 22.↵
    1. Sullivan HW,
    2. Squire C,
    3. Aikin KJ,
    4. et al

    . Physicians' use of and preferences for FDA-approved prescribing information. Res Social Adm Pharm 2022;18:3027–37.

    OpenUrlPubMed